tiprankstipranks
Senzime AB (SE:SEZI)
:SEZI
Want to see SE:SEZI full AI Analyst Report?

Senzime AB (SEZI) Price & Analysis

2 Followers

SEZI Stock Chart & Stats

kr5.13
-kr0.14(-2.60%)
At close: 4:00 PM EST
kr5.13
-kr0.14(-2.60%)

Bulls Say, Bears Say

Bulls Say
Recurring Consumables Momentum (sensor Volumes)A large and growing installed base driving recurring sensor consumption creates durable revenue visibility and gross-margin leverage. Hitting 1M monitored patients and strong sensor volume growth implies predictable blade sales, helping stabilize revenue streams and margins over time.
Underlying Gross Margin Expansion And Pricing PowerHigh underlying gross margins from consumables and executed ASP increases imply structural profitability potential as scale rises. Sustained margin expansion from pricing and volume is a durable path to convert revenue into cash once fixed costs and sales execution normalize.
Installed Base Growth & New Service Model AdoptionA growing installed base plus traction with an As‑a‑Service model supports recurring revenue and faster deal closures. More deployed monitors increase consumable attachment rates and create a durable revenue funnel from both capital sales and higher-margin recurring service streams.
Bears Say
Large Operating Cash Burn And Negative FCFSustained negative operating cash flow and free cash burn require external funding or use of credit lines, constraining strategic flexibility. Even with margin improvements, the company must materially reduce cash burn or raise capital to sustain operations and execute growth initiatives without dilution.
Revenue Deceleration And Deeply Negative ProfitabilityA reversal to negative top‑line growth combined with extreme negative operating margins indicates the business has not yet achieved scale to absorb fixed costs. Without reaccelerating sales or cutting structural costs, profitability and return metrics will remain impaired and equity can erode.
Adoption, Sales‑cycle And Regulatory Timing RisksLengthy hospital procurement, clinician adoption hurdles and regulatory timing (esp. in Asia) create lumpy, delayed revenue realization. These structural go‑to‑market frictions can postpone recurring consumable flows and pressure cash‑flow targets despite product merit and installed base growth.

Senzime AB News

SEZI FAQ

What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was kr3.85 and its highest was kr7.38 in the past 12 months.
    What is Senzime AB’s market cap?
    Senzime AB’s market cap is kr682.31M.
      When is Senzime AB’s upcoming earnings report date?
      Senzime AB’s upcoming earnings report date is Jul 16, 2026 which is in 33 days.
        How were Senzime AB’s earnings last quarter?
        Senzime AB released its earnings results on Apr 22, 2026. The company reported -kr0.143 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.143.
          Is Senzime AB overvalued?
          According to Wall Street analysts Senzime AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Senzime AB pay dividends?
            Senzime AB does not currently pay dividends.
            What is Senzime AB’s EPS estimate?
            Senzime AB’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Senzime AB have?
            Senzime AB has 157,215,040 shares outstanding.
              What happened to Senzime AB’s price movement after its last earnings report?
              Senzime AB reported an EPS of -kr0.143 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.901%.
                Which hedge fund is a major shareholder of Senzime AB?
                Currently, no hedge funds are holding shares in SE:SEZI
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Senzime AB

                  Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.

                  Senzime AB (SEZI) Earnings & Revenues

                  SEZI Company Deck

                  SEZI Earnings Call

                  Q4 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The call conveyed a generally positive outlook: the company reported strong underlying operational momentum (notably sensor growth, a 1M monitored‑patient milestone, margin improvement, new business models like TetraGraph‑as‑a‑Service, TetraCom and important customer wins) while acknowledging a temporary Q1 growth dip driven by delayed U.S. deals, FX and tariff headwinds and some regional regulatory timing issues. Management emphasizes cost discipline, a solid pipeline, available funding and confidence in meeting full‑year objectives, but execution (recovering delayed deals, FX/tariff resolution and regulatory rollouts) is needed to realize targets.View all SE:SEZI earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Bactiguard Holding AB
                  C-Rad AB Class B
                  Integrum AB Class B
                  Sedana Medical AB
                  OssDsign AB

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks